U.S. Markets close in 25 mins.

AstraZeneca PLC (AZN)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
33.88-0.02 (-0.06%)
As of 3:35PM EDT. Market open.
People also watch
Interactive chart
Previous Close33.90
Bid0.00 x
Ask0.00 x
Day's Range33.82 - 34.12
52 Week Range25.55 - 35.04
Avg. Volume4,378,824
Market Cap84.13B
PE Ratio (TTM)25.38
Earnings DateN/A
Dividend & Yield1.90 (5.60%)
Ex-Dividend Date2017-02-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters1 hour ago

    Severe asthma drug shows AstraZeneca promise beyond cancer

    AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Benralizumab will compete with GlaxoSmithKline's Nucala and Teva's Cinqair - two other new antibody drugs for severe asthma - but AstraZeneca believes its product's potency and convenient dosing could give it an edge. While most investor focus is on AstraZeneca's cancer research, particularly the immunotherapy drug durvalumab , the company also has a long history in respiratory therapy that it plans to build on with benralizumab.

  • InPlay from Briefing.com
    Briefing.com38 minutes ago

    InPlay from Briefing.com

    InPlay from Briefing.com

  • Financial Times4 hours ago

    [$$] AstraZeneca sells Seloken European rights for $300m

    AstraZeneca, the Anglo-Swedish pharmaceuticals group, has sold the European commercial rights to its Seloken heart medicines in a deal worth more than $300m, as it moves to focus on new products in what ...